Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

Klondike Golden Moments

Foreword: This tale grew from a chance nugget discovery along the shore of a humble Yukon creek carving through the remote Territory and became the great history of the Klondike Gold Rush. Join author James Kwantes as he touches down in the Yukon with 12 exciting stories and c...
James Kwantes | August 15, 2019 |

From a Failed Breakout to a Failed Breakdown

The historical action of the precious metals sector over the past few weeks has continued. The strong recovery in GDX, GDXJ, and Silver has potentially invalidated the technical breakdown that occurred during the crash. It appears to be a failed breakdown. Furthermor...
Jordan Roy-Byrne, CMT | March 30, 2020 |

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. In a May 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed why the outlook is positive for Daré Bioscience In...
Streetwise Reports | May 21, 2020 |

Failed Breakouts Take a Heavy Toll on the Oil Bulls

The bulls certainly made a strong run yesterday but didn’t finish the day on a strong note in the least. That’s an understatement, actually. They’ve given up almost all of their gains, closing below the many important resistances...
Nadia Simmons | September 6, 2019 |

‘Power to the People’ and mining

The 1960s and 70s were decades of incredible social upheaval. Fed up with wars, governments out of touch with their ideals, authority figures who didn’t get them, the “flower children” of the '60s took to the streets to demand equal ri...
Richard (Rick) Mills | November 4, 2019 |

My two favourite stocks for generating income

In last week's DailyWealth, Steve Sjuggerud published compelling research suggesting the worst is past and there's another bubble coming. The Federal Reserve is the reason. We've never before seen recessions when the Federal Reserve is in "accommodating" mode and interest ra...
Tom Dyson | October 28, 2012 |

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. Biopharmaceutical firm Retrophin Inc. (RTRX:NASDAQ) shares are trading much lower today as the co...
Streetwise Reports | August 26, 2019 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |
1 2 3 4 5 6 7 8 9 10 ...